Premium
Nanotechnology and human health: risks and benefits
Author(s) -
Cattaneo Anna Giulia,
Gornati Rosalba,
Sabbioni Enrico,
ChirivaInternati Maurizio,
Cobos Everardo,
Jenkins Marjorie R.,
Bernardini Giovanni
Publication year - 2010
Publication title -
journal of applied toxicology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.784
H-Index - 87
eISSN - 1099-1263
pISSN - 0260-437X
DOI - 10.1002/jat.1609
Subject(s) - nanocarriers , nanotechnology , human health , nanomaterials , in silico , risk analysis (engineering) , chemistry , drug delivery , medicine , materials science , biochemistry , environmental health , gene
Nanotechnology is expected to be promising in many fields of medical applications, mainly in cancer treatment. While a large number of very attractive exploitations open up for the clinics, regulatory agencies are very careful in admitting new nanomaterials for human use because of their potential toxicity. The very active research on new nanomaterials that are potentially useful in medicine has not been counterbalanced by an adequate knowledge of their pharmacokinetics and toxicity. The different nanocarriers used to transport and release the active molecules to the target tissues should be treated as additives, with potential side effects of themselves or by virtue of their dissolution or aggregation inside the body. Only recently has a systematic classification of nanomaterials been proposed, posing the basis for dedicated modeling at the nanoscale level. The use of in silico methods, such as nano‐QSAR and PSAR, while highly desirable to expedite and rationalize the following stages of toxicological research, are not an alternative, but an introduction to mandatory experimental work. Copyright © 2010 John Wiley & Sons, Ltd.